CRISPR RiPCA for Investigating eIF4E-m 7 GpppX Capped mRNA Interactions
ACS Chemical Biology · 15.08.2025 · 20 (8) · 2038-2048
DOI: 10.1021/acschembio.5c00471 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 07.08.2025. Verfasst von Gabriela Vega-Hernández und 7 weiteren Autor:innen. Beteiligte Einrichtung: Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: Eukaryotic Initiation Factor-4E, RNA, Messenger, CRISPR-Cas Systems, RNA Caps. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, Michigan Center for Therapeutic Innovation, University of Michigan.
Abstract (Originalsprache)
Post-transcriptional modifications expand the information encoded by an mRNA. These dynamic and reversible modifications are specifically recognized by reader RNA-binding proteins (RBPs), which mediate the regulation of gene expression, RNA processing, localization, stability, and translation. Given their crucial functions, any disruptions in the normal activity of these readers can have significant implications for cellular health. Consequently, the dysregulation of these RBPs has been associated with neurodegenerative disorders, cancers, and viral infections. Therefore, there has been growing interest in targeting reader RBPs as a potential therapeutic strategy since developing molecules that restore proper RNA processing and function may offer a promising avenue for treating diseases. In this work, we coupled our previously established live-cell RNA-protein interaction (RPI) assay, RNA interaction with Protein-mediated Complementation Assay (RiPCA), with CRISPR technology to build a new platform, CRISPR RiPCA. As a model for development, we utilized the interaction of eukaryotic translation initiation factor 4E (eIF4E), a reader RBP that binds to the m7GpppX cap present at the 5' terminus of coding mRNAs, with an m7G capped RNA substrate. Using eIF4E CRISPR RiPCA, we demonstrate our technology's potential for measuring on-target activity of inhibitors of the eIF4E RPI of relevance to cancer drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Michigan Center for Therapeutic Innovation, Michigan Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Promega Corporation, San Luis Obispo, California 93401, United States.
ORCID-Profile: Amanda L Garner
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- Michigan Center for Therapeutic Innovation, University of Michigan
Zitieren
APA
Vega-Hernández, G., Duque, J., Klein, B. J. C., Soueid, D. M., Rech, J. C., Wang, H., Zhou, W., & Garner, A. L. (2025). CRISPR RiPCA for Investigating eIF4E-m 7 GpppX Capped mRNA Interactions. ACS Chemical Biology, 20(8), 2038-2048. https://doi.org/10.1021/acschembio.5c00471
Vancouver
Vega-Hernández G, Duque J, Klein BJC, Soueid DM, Rech JC, Wang H, et al. CRISPR RiPCA for Investigating eIF4E-m 7 GpppX Capped mRNA Interactions. ACS Chemical Biology. 2025;20(8):2038-2048. doi:10.1021/acschembio.5c00471
BibTeX
@article{VegaHernndez2025,
author = {Vega-Hernández, Gabriela and Duque, Jesse and Klein, Brandon J C and Soueid, Dalia M and Rech, Jason C and Wang, Hui and Zhou, Wenhui and Garner, Amanda L},
title = {CRISPR RiPCA for Investigating eIF4E-m 7 GpppX Capped mRNA Interactions},
journal = {ACS Chemical Biology},
year = {2025},
volume = {20},
number = {8},
pages = {2038--2048},
doi = {10.1021/acschembio.5c00471}
}
EUVIMED